AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01518725 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
Study NCT04383028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MELD algorithm use to aid in the planning of SEEG electrode trajectories
Description: During the routine SEEG planning meetings, the planning of SEEG trajectories, including the number and location of electrodes, will follow the usual clinical pathway and be planned according to the expertise of the attending neurosurgeon, neurophysiologist and neurologist at the multidisciplinary team meeting. Once the trajectories have been planned, anonymised scans for each patient (linked to them via a unique study ID) will be run through the MELD classifier and the top 3 MELD identified lesion clusters will be considered for further implantation.~These top 3 MELD classifier identified clusters will then be merged with the existing clinical plan to assess if each of the clusters are already being sampled by an SEEG electrode. If there is already an electrode in each lesion, no adjustments will be made. If there are clusters that are not being recorded from, and it is technically possible, extra electrodes (up to 3) will be added to record from these additional locations.
Study NCT03147378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
Study NCT00810771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Information
Description: A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.
Study NCT00810771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Information
Description: A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.
Study NCT00810771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preference-tailored Information
Description: A preference elicitation exercise that will generate a list of the three top attributes for the subject and the CRC screening test most consistent with these attributes. Subjects will be provided with a handout to take to their clinic appointment as the Standard Information group does, but with the addition of a listing of their top attributes and the test most consistent with their top attributes.
Study NCT04492748 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Collagen and platelet rich plasma (PRP)
Description: Ultrasound guided injections
Study NCT04492748 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen
Description: Ultrasound guided injections
Study NCT04492748 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma (PRP)
Description: Ultrasound guided injections
Study NCT00848835 — intervention group
Intervention type: DEVICE
Intervention: defibrillation lead (ENDOTAK EZ and RELIANCE)
Description: defibrillation lead
Study NCT02827760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synergy1
Description: Inulin type fructans
Study NCT02827760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study NCT02808325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelaspan 4%
Description: Gelaspan 4% combined with Sterofundin ISO
Study NCT02808325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelofusine 4%
Description: Gelofusine 4% combined with Sodium Chloride
Study NCT02110186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Stabilization
Study NCT02110186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discectomy
Study NCT02110186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discectomy
Study NCT02110186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Instrumentation and fusion
Study NCT02303210 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: hearing aid NaidaUP
Description: Standard Power Hearing instruments including different frequency lowering techniques
Study NCT02303210 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: hearing aid NaidaSP
Description: Standard Power Hearing instruments including different frequency lowering techniques
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CSB drum dried + α-amylase
Description: CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CSB drum dried + α-amylase
Description: CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CSB + α-amylase
Description: CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CSB + α-amylase
Description: CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RSB + α-amylase
Description: RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: RSB + α-amylase
Description: RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: WSB + α-amylase
Description: WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CSB PLUS drum dried + α-amylase
Description: CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CSB PLUS drum dried + α-amylase
Description: CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CSB PLUS + α-amylase
Description: CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CSB PLUS + α-amylase
Description: CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RSB PLUS + α-amylase
Description: RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: RSB PLUS + α-amylase
Description: RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: WSB PLUS + α-amylase
Description: WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: WSB PLUS + α-amylase
Description: WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Commercial porridge flour
Description: Porridge from commercial porridge flour
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Commercial porridge bar
Description: Porridge from commercial porridge bar
Study NCT02192892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Commercial MSB + α-amylase
Description: Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
Study NCT00750035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy
Description: Total abdominal hysterectomy and Subtotal abdominal hysterectomy
Study NCT00750035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtotal abdominal hysterectomy
Study NCT04413214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrimycin
Description: The study involves three dose groups: 200mg, 400mg and 600mg. Three patients are planned for each dose group. Starting from the low dose group, the treatment to three patients in the 200mg dose group: 200mg of Carrimycin after meals every morning (po) for three weeks, and then discontinue for one week, the tolerance and efficacy evaluation will be performed after the 4 weeks. DLT will be recorded during the 4 weeks.
Study NCT03260855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires/Scales
Description: Scale of Fear of Cancer Recurrence Inventory, Hospital Anxiety and Depression Scale, Evaluation of stress and life quality.
Study NCT03260855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Human blood sample
Description: The intervention is based on blood test.
Study NCT04442633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine Cap/Tab
Description: Glutamine Capsules: One capsule three times daily on an empty stomach for one month
Study NCT04442633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconazole Oral gel
Description: Miconazole oral gel: applied three to four times daily for three weeks
Study NCT04442633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconazole Oral gel
Description: Miconazole oral gel: applied three to four times daily for three weeks
Study NCT04442633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenacort in orabase
Description: Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached
Study NCT04442633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenacort in orabase
Description: Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached
Study NCT04961346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrapro® mesh
Description: large-pore, lightweight polypropylene mesh
Study NCT04961346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Premilene® mesh
Description: small-pore, heavyweight polypropylene mesh
Study NCT01901289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® PTX® Drug-Eluting Peripheral Stent
Description: Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
Study NCT01763853 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 4% albumin
Study NCT04132141 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality Headset with curated content
Description: clinicians will wear VR immersive headset for up to 15 minutes during their break
Study NCT01340066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UISH001
Description: sublingual dosing, 1 drop 3 times a day
Study NCT01340066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: sublingual dosing,1 drop 3 times a day
Study NCT00578916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRI (BMS-690514)
Description: Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
Study NCT02789020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.
Study NCT02789020 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo tablet will be taken for one year, once a day, and at the same dose of 1mg. subjects will undergo functional and structural brain imaging to be compared with the group taking the rasagiline intervention.
Study NCT02789020 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: This test will be performed at baseline and one year.
Study NCT01144416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 900962 / Corifollitropin alfa / Org 36286
Description: SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
Study NCT01144416 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RecFSH / follitropin beta
Description: RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
Study NCT01144416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for SCH 900962
Description: Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall.
Study NCT01144416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for recFSH
Description: Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
Study NCT02595866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy
Description: Given PO
Study NCT02595866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT02595866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02595866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT02595866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02595866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT01072136 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule will be filled with lactose and be identical in appearance to the capsule with the active ingredient.
Study NCT01072136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
Study NCT01072136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Single dose will consist of 1 over-encapsulated capsule (400 mg) administered orally.
Study NCT01294111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Description: Three groups with 15 participants each will complete a 60 minutes tai chi training programme twice-weekly for 16 weeks. The programme is worked out by an expert in Chinese traditional medicine to suit elderly people with chronic heart failure, and the classes are led by experienced leaders.
Study NCT00062491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karenitecin (BNP1350)
Description: Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR\< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.
Study NCT00319202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 32 mg/d for 6 months
Study NCT00319202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration for 6 months
Study NCT05129163 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.
Study NCT05129163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.
Study NCT05129163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition activities
Description: The intervention programs included: (a) training on-site staffs to use motivational interview techniques to communicate, to estimate participant's energy requirements, and to learn how to provide proper amounts of foods to individual elderlies, (b) nutrition grouped activities on ①know my plate, ②wholegrains, ③ drinking teas with dairy, and nuts, ④novel ways to eat fruit and vegetables, ⑤healthy breakfast ideas. In the first month, participants were intervened with the activities laid out above; in the second month, participants were intervened with qualitative discussion on elders' dietary changes; in the third month, participants were intervened with designed activities that helped break down barriers in order to establish a long-term change in dietary habits.
Study NCT01744067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: 2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
Study NCT01744067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules 3 times a day (oral administration)
Study NCT01878578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Tablets containing ESL 600 mg
Study NCT01878578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenytoin
Description: Hidantina® tablets containing 100 mg of phenytoin
Study NCT01878578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets containing matching placebo
Study NCT01779336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL225B
Description: * Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~* This 21 day administration will define a treatment cycle.~* Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified.
Study NCT00873821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
Study NCT00873821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
Study NCT03776318 — intervention group
Intervention type: DRUG
Intervention: Long-Term Safety Follow-up
Description: STX-015-18-01 long-term safety follow-up
Study NCT03150290 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Indirect Calorimetry.
Description: REE measurement
Study NCT03150290 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 18-FDG-PET
Description: 18-FDG-PET
Study NCT02689206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
Study NCT03174561 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: diet restriction
Description: diet restriction for 28 days
Study NCT02011672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrient-enriched milk